The effect of biologics on patients with nasal polyp eosinophilia.

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a condition where the lining of the nasal passages and sinuses becomes persistently inflamed, forming soft growths called polyps that block breathing, affect smell, and cause facial pain. In some patients, this is driven by a type of white blood cell called eosinophils. Dupilumab is a biologic medication that blocks a key inflammatory pathway linked to eosinophil-driven disease. This Phase 2 study from Griffith University will treat 25 adults with uncontrolled eosinophilic nasal polyp disease with dupilumab for 26 weeks. Using cutting-edge tissue analysis platforms, researchers will track exactly how the tissue in the nasal lining changes at a molecular and cellular level at multiple time points — providing detailed insight into how dupilumab works in this condition. You may be eligible if you are an adult (18+) with nasal polyp eosinophilia that is not adequately controlled by standard treatments, and you are not currently on dupilumab, mepolizumab, or benralizumab. People with known hypersensitivity to dupilumab, immune deficiency, cystic fibrosis, or conditions that elevate eosinophils for other reasons (such as Churg-Strauss syndrome) are not eligible.